lipoprotein (a): a bad actor
A recent Mendelian randomization trial found a profound atherogenic effect for lipoprotein(a), significantly more so than LDL (see lipids Lp(a) more atherogen than LDL JACC2024 in dropbox or doi.org/10.1016/j.jacc.2023.10.039) Details : -- these researchers used 2 genomic databases to assess the role of lipoprotein(a), referred to as Lp(a), versus LDL in terms of atherogenicity, on a per-particle basis. They were able to assess the individual particles in both of these lipid moieties by measuring the apolipoproteinB (apoB) concentrations (each one of these lipid moieties has a single apoB on its membrane) -- they accessed the UK Biobank population of 502,413 UK residents of mainly European ancestry and 54% female -- as a replication cohort, they accessed the CARDIoGRAMplusC4D data sets (Coronary ARtery DIsease Genome-wide Replication and Meta-analysis, plus The Coronary Artery Disease Genetics), with 98 of the Lp(a) cluster SNPs (single nucleotide polymorphisms) and 130